CTLA4 and posterior cortical atrophy: A clinical study combining anti-CTLA4 with a 8 Gy fraction to PCa bony metastases demonstrated a non-significant improvement in overall survival,32,33 and a trial investigating the efficacy of anti-PD-1 and RT in high-risk and oligometastatic PCa is underway.34